Immune clearance of highly pathogenic SIV infection

Scott G. Hansen, Michael Piatak, Abigail B. Ventura, Colette M. Hughes, Roxanne M. Gilbride, Julia C. Ford, Kelli Oswald, Rebecca Shoemaker, Yuan Li, Matthew S. Lewis, Awbrey N. Gilliam, Guangwu Xu, Nathan Whizin, Benjamin J. Burwitz, Shannon L. Planer, John M. Turner, Alfred W. Legasse, Michael K. Axthelm, Jay A. Nelson, Klaus Früh, Jonah B. Sacha, Jacob D. Estes, Brandon F. Keele, Paul T. Edlefsen, Jeffrey D. Lifson () and Louis J. Picker ()
Additional contact information
Scott G. Hansen: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Michael Piatak: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Abigail B. Ventura: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Colette M. Hughes: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Roxanne M. Gilbride: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Julia C. Ford: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Kelli Oswald: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Rebecca Shoemaker: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Yuan Li: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Matthew S. Lewis: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Awbrey N. Gilliam: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Guangwu Xu: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Nathan Whizin: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Benjamin J. Burwitz: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Shannon L. Planer: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
John M. Turner: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Alfred W. Legasse: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Michael K. Axthelm: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Jay A. Nelson: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Klaus Früh: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Jonah B. Sacha: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Jacob D. Estes: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Brandon F. Keele: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Paul T. Edlefsen: Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center
Jeffrey D. Lifson: AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA
Louis J. Picker: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University

Nature, 2013, vol. 502, issue 7469, 100-104

Abstract: Cellular immune responses in rhesus macaques (Macaca mulatta) vaccinated with cytomegalovirus vectors expressing SIV proteins are able to stringently control highly pathogenic SIV infection, regardless of the route of challenge, after systemic spread; immunological and virological analyses of protected macaques followed for up to 3 years suggest that persistent immune surveillance by vaccine-elicited immune responses may have cleared the infection.

Date: 2013
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature12519 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:502:y:2013:i:7469:d:10.1038_nature12519

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature12519

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().